Inventor
KALLEN KARL-JOSEF
DE29 patents
⚠️ This page may combine multiple inventors who share the name “KALLEN KARL-JOSEF”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CUREVAC AG
19 patentsUS10434158B2Oct 8, 2019
Combination of vaccination and inhibition of the PD-1 pathway
CUREVAC AG31 citations98
US10117920B2Nov 6, 2018
Combination of vaccination and inhibition of the PD-1 pathway
CUREVAC AG32 citations98
US9974845B2May 22, 2018
Combination of vaccination and inhibition of the PD-1 pathway
CUREVAC AG32 citations98
US11266735B2Mar 8, 2022
Combination vaccine
CUREVAC AG40 citations97
US10918740B2Feb 16, 2021
RNA containing composition for treatment of tumor diseases
CUREVAC AG38 citations97
US10729761B2Aug 4, 2020
Vaccination in newborns and infants
CUREVAC AG30 citations97
US10596252B2Mar 24, 2020
Vaccination in newborns and infants
CUREVAC AG30 citations97
US10293058B2May 21, 2019
RNA containing composition for treatment of tumor diseases
CUREVAC AG50 citations97
US10172935B2Jan 8, 2019
Vaccination in newborns and infants
CUREVAC AG33 citations97
US11458195B2Oct 4, 2022
Combination of vaccination and inhibition of the PD-1 pathway
CUREVAC AG12 citations94
US10588959B2Mar 17, 2020
Combination vaccine
CUREVAC AG30 citations94
US10568958B2Feb 25, 2020
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
CUREVAC AG30 citations94
US10869935B2Dec 22, 2020
RNA containing composition for treatment of tumor diseases
CUREVAC AG29 citations93
US11110157B2Sep 7, 2021
Combination of vaccination and OX40 agonists
CUREVAC AG28 citations92
US10307472B2Jun 4, 2019
Combination of vaccination and OX40 agonists
CUREVAC AG31 citations92
US11458193B2Oct 4, 2022
Combination of vaccination and inhibition of MHC class I restricted antigen presentation
CUREVAC AG11 citations83
US12337031B2Jun 24, 2025
Combination vaccine
CUREVAC AG0 citations62
US11672856B2Jun 13, 2023
Vaccination in newborns and infants
CUREVAC AG0 citations62
US12178863B2Dec 31, 2024
Combination of vaccination and OX40 agonists
CUREVAC AG0 citations61
CureVac SE
5 patentsUS11690910B2Jul 4, 2023
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
CureVac SE6 citations74
US12447209B2Oct 21, 2025
Combination of vaccination and inhibition of the PD-1 pathway
CureVac SE0 citations62
US12390520B2Aug 19, 2025
Vaccination in newborns and infants
CureVac SE0 citations62
US12036277B2Jul 16, 2024
Vaccination with mRNA-coded antigens
CureVac SE0 citations62
US11975064B2May 7, 2024
Vaccination with mRNA-coded antigens
CureVac SE0 citations62
BAUMHOF PATRICK
2 patentsUS8968746B2Mar 3, 2015
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
BAUMHOF PATRICK70 citations96
US9421255B2Aug 23, 2016
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
BAUMHOF PATRICK34 citations93